Opioid-Sparing Analgesia After Laparoscopic Gastrectomy: Exploratory Clinical Outcomes and Cine-MRI Assessment of Small-Bowel Motility.

J Vis ExpOct 1, 2026 (epub)
Clinical ResearchGastroenterologyGeneral SurgeryRadiology (Diagnostic)

Yijun Liu, Xinjuan Tan, Jian Mo et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated opioid-sparing multimodal analgesia versus conventional opioid analgesia in 130 patients undergoing laparoscopic radical gastrectomy. The opioid-sparing group had a significantly lower incidence of postoperative ileus (9.2% vs 26.2%, p = 0.0201) and improved gastrointestinal motility assessed by cine-MRI.

Key findings

  • Postoperative ileus occurred in 9.2% of the opioid-sparing group compared to 26.2% in the conventional group.
  • The opioid-sparing group demonstrated higher contraction frequency and amplitude on cine-MRI assessments.
  • Patients in the opioid-sparing group reported lower pain scores and had shorter gastrointestinal recovery times.

Why it matters

The findings suggest that opioid-sparing analgesia may enhance recovery and reduce complications such as postoperative ileus in patients undergoing laparoscopic gastrectomy, which is crucial for improving surgical outcomes.

Source

PubMed · PMID 42825486

Published in J Vis Exp. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.